Dashboard
Manage Tickers

RYTMRHYTHM PHARMACEUTICALS, INC.

Nasdaq rhythmtx.com


$ 42.71 $ -1.60 (-3.61 %)    

Friday, 14-Jun-2024 15:59:57 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 479.30 $ 2.47 (0.52 %)
DIA $ 386.46 $ -0.42 (-0.11 %)
SPY $ 542.65 $ 0.33 (0.06 %)
TLT $ 94.67 $ 0.79 (0.84 %)
GLD $ 215.76 $ 2.76 (1.3 %)
$ 42.77
$ 44.75
$ 0.00 x 0
$ 42.77 x 100
$ 42.38 - $ 45.86
$ 15.50 - $ 52.57
748,294
na
2.61B
$ 1.04
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-07-2024 03-31-2024 10-Q
2 02-29-2024 12-31-2023 10-K
3 11-08-2023 09-30-2023 10-Q
4 08-01-2023 06-30-2023 10-Q
5 05-02-2023 03-31-2023 10-Q
6 03-01-2023 12-31-2022 10-K
7 11-08-2022 09-30-2022 10-Q
8 08-03-2022 06-30-2022 10-Q
9 05-03-2022 03-31-2022 10-Q
10 03-01-2022 12-31-2021 10-K
11 11-02-2021 09-30-2021 10-Q
12 08-03-2021 06-30-2021 10-Q
13 05-03-2021 03-31-2021 10-Q
14 03-01-2021 12-31-2020 10-K
15 11-02-2020 09-30-2020 10-Q
16 08-03-2020 06-30-2020 10-Q
17 05-04-2020 03-31-2020 10-Q
18 03-02-2020 12-31-2019 10-K
19 11-01-2019 09-30-2019 10-Q
20 07-29-2019 06-30-2019 10-Q
21 05-03-2019 03-31-2019 10-Q
22 03-08-2019 12-31-2018 10-K
23 11-09-2018 09-30-2018 10-Q
24 08-08-2018 06-30-2018 10-Q
25 05-14-2018 03-31-2018 10-Q
26 03-12-2018 12-31-2017 10-K
27 11-14-2017 09-30-2017 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

rhythm-pharmaceuticals-grants-inducement-equity-covering-56080-shares-to-ten-new-employees
Rhythm Pharmaceuticals Grants Inducement E...
06/11/2024 20:02:03

Including Options For 9,230 Shares And RSUs For 46,850 Shares

rhythm-pharmaceuticals-presents-first-patient-and-caregiver-reported-experiences-from-phase-2-trial-of-setmelanotide-in-hypothalamic-obesity-at-endo-2024
Rhythm Pharmaceuticals Presents First Pati...
06/03/2024 20:04:43

- Participants from the completed Phase 2 hypothalamic obesity trial reported positive changes in sleep, energy levels during s...

rhythm-pharmaceuticals-announced-that-the-national-institute-for-health-and-care-excellence-issued-guidance-that-recommends-imcivree-setmelanotide-as-an-option-for-treatment-of-obesity-and-hyperphagia-in-patients-with-bardet-biedl-syndrome
Rhythm Pharmaceuticals Announced That The ...
05/22/2024 08:02:12

canaccord-genuity-maintains-buy-on-rhythm-pharmaceuticals-lowers-price-target-to-79
Canaccord Genuity Maintains Buy on Rhythm ...
05/08/2024 16:55:55

Canaccord Genuity analyst Whitney Ijem maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and lowers the price target...

b-of-a-securities-downgrades-rhythm-pharmaceuticals-to-neutral-lowers-price-target-to-42
B of A Securities Downgrades Rhythm Pharma...
05/08/2024 10:17:30

B of A Securities analyst Tazeen Ahmad downgrades Rhythm Pharmaceuticals (NASDAQ:RYTM) from Buy to Neutral and lowers the pr...

needham-maintains-buy-on-rhythm-pharmaceuticals-lowers-price-target-to-46
Needham Maintains Buy on Rhythm Pharmaceut...
05/07/2024 18:11:57

Needham analyst Joseph Stringer maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and lowers the price target from $...

rhythm-pharmaceuticals-q1-2024-gaap-eps-235-misses-212-estimate-sales-25967m-miss-26896m-estimate
Rhythm Pharmaceuticals Q1 2024 GAAP EPS $(...
05/07/2024 11:02:02

rhythm-pharmaceuticals-presents-data-from-phase-3-pediatrics-trial-at-pediatric-endocrine-society-annual-meeting
Rhythm Pharmaceuticals Presents Data From ...
05/06/2024 12:15:08

-- Oral presentation showcased previously disclosed data that demonstrate setmelanotide achieved 3.04 mean reduction in BMI-Z s...

rhythm-pharmaceuticals-announces-publication-of-results-from-phase-2-study-of-setmelanotide-for-the-treatment-of-hypothalamic-obesity-in-the-lancet-diabetes--endocrinology
Rhythm Pharmaceuticals Announces Publicati...
04/29/2024 22:49:41

- Publication highlights administration of setmelanotide therapy resulted in a mean percent reduction in BMI of 15% at 16 weeks...

analyst-expectations-for-rhythm-pharmaceuticalss-future
Analyst Expectations For Rhythm Pharmaceut...
04/26/2024 13:01:18

needham-reiterates-buy-on-rhythm-pharmaceuticals-maintains-50-price-target
Needham Reiterates Buy on Rhythm Pharmaceu...
04/26/2024 10:39:34

Needham analyst Joseph Stringer reiterates Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and maintains $50 price target.

jim-cramer-is-willing-to-let-this-pharma-stock-catch-fire-advises-not-to-sell-mckesson
Jim Cramer Is 'Willing To Let This Pharma ...
04/19/2024 12:46:13

The "Mad Money" host recommended buying some Marvell Technology, and then wait until under $60 to buy the rest.

wells-fargo-maintains-overweight-on-rhythm-pharmaceuticals-lowers-price-target-to-52
Wells Fargo Maintains Overweight on Rhythm...
04/18/2024 12:59:42

Wells Fargo analyst Derek Archila maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and lowers the price targ...

5-analysts-assess-rhythm-pharmaceuticals-what-you-need-to-know
5 Analysts Assess Rhythm Pharmaceuticals: ...
04/10/2024 16:00:49

needham-reiterates-buy-on-rhythm-pharmaceuticals-maintains-50-price-target
Needham Reiterates Buy on Rhythm Pharmaceu...
04/10/2024 10:26:02

Needham analyst Joseph Stringer reiterates Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and maintains $50 price target.

rhythm-pharmaceuticals-announces-first-patient-dosed-in-phase-1-trial-evaluating-rm-718
Rhythm Pharmaceuticals Announces First Pat...
03/25/2024 12:04:49

- Three-part study to evaluate safety, tolerability and pharmacokinetics now underway -- -- RM-718 showed potential to reduce b...

analyst-expectations-for-rhythm-pharmaceuticalss-future
Analyst Expectations For Rhythm Pharmaceut...
02/22/2024 18:00:42

needham-reiterates-buy-on-rhythm-pharmaceuticals-maintains-50-price-target
Needham Reiterates Buy on Rhythm Pharmaceu...
02/22/2024 17:25:18

Needham analyst Joseph Stringer reiterates Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and maintains $50 price target.

rhythm-pharmaceuticals-announced-plans-to-add-a-cohort-of-patients-with-hypothalamic-obesity-in-japan-to-its-ongoing-global-phase-3-clinical-trial-of-setmelanotide-with-dosing-expected-to-begin-in-the-third-quarter-of-2024
Rhythm Pharmaceuticals Announced Plans To ...
02/22/2024 12:09:24

rhythm-pharmaceuticals-says-cash-on-hand-of-601m-sufficient-to-fund-planned-operations-into-the-second-half-of-2025
Rhythm Pharmaceuticals Says Cash On-hand O...
02/22/2024 12:08:44

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

06/28/2024 Malibu Boats, Inc. (MBUU)
07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)
07/01/2024 Equinix, Inc. (EQIX)
07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)

NEW CASE INVESTIGATION

AnaptysBio Inc (ANAB)